Clinton Hall, Sandra Maduforo, Celeste J Romano, Anna T Bukowinski, Gia R Gumbs, Ava Marie S Conlin
{"title":"Receipt of Tdap or Influenza Vaccine During Pregnancy and Odds of Clinical Chorioamnionitis: A Nested Case-Control Study.","authors":"Clinton Hall, Sandra Maduforo, Celeste J Romano, Anna T Bukowinski, Gia R Gumbs, Ava Marie S Conlin","doi":"10.1002/pds.70147","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the odds of clinical chorioamnionitis following tetanus, diphtheria, and acellular pertussis (Tdap) or influenza vaccine receipt in pregnancy.</p><p><strong>Methods: </strong>In this nested case-control study, a cohort of live deliveries at two United States military hospitals, 2013-2018, was initially screened for chorioamnionitis using diagnosis codes. A sample of deliveries was selected for chart review and validation. Study cases (clinical chorioamnionitis) were defined by the presence of fever and at least one additional clinical symptom during the delivery hospitalization; controls were defined by the absence of these criteria. Descriptive statistics compared characteristics of validated cases and controls, and multivariable logistic regression models estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) with receipt of Tdap or influenza vaccine during pregnancy; observations were weighted by the inverse probability of being sampled for validation.</p><p><strong>Results: </strong>Among 6931 deliveries, 1868 were sampled for validation and 1650 (n = 305 cases, n = 1345 controls) were included for analysis. At delivery, mean age was 25.0 years for cases and 25.9 years for controls; 88.4% of cases and 63.0% of controls were primipara. Tdap vaccine was recorded in 82.8% of cases and 82.0% of controls (aOR 0.94, 95% CI 0.72, 1.23) and influenza vaccine was recorded in 61.8% of cases and 63.0% of controls (aOR 0.97, 95% CI 0.78, 1.19). Analyses that considered timing and combinations of vaccine receipt yielded similar estimates.</p><p><strong>Conclusion: </strong>In this population, neither Tdap nor influenza vaccine receipt during pregnancy was associated with increased odds of clinical chorioamnionitis at delivery.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 4","pages":"e70147"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the odds of clinical chorioamnionitis following tetanus, diphtheria, and acellular pertussis (Tdap) or influenza vaccine receipt in pregnancy.
Methods: In this nested case-control study, a cohort of live deliveries at two United States military hospitals, 2013-2018, was initially screened for chorioamnionitis using diagnosis codes. A sample of deliveries was selected for chart review and validation. Study cases (clinical chorioamnionitis) were defined by the presence of fever and at least one additional clinical symptom during the delivery hospitalization; controls were defined by the absence of these criteria. Descriptive statistics compared characteristics of validated cases and controls, and multivariable logistic regression models estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) with receipt of Tdap or influenza vaccine during pregnancy; observations were weighted by the inverse probability of being sampled for validation.
Results: Among 6931 deliveries, 1868 were sampled for validation and 1650 (n = 305 cases, n = 1345 controls) were included for analysis. At delivery, mean age was 25.0 years for cases and 25.9 years for controls; 88.4% of cases and 63.0% of controls were primipara. Tdap vaccine was recorded in 82.8% of cases and 82.0% of controls (aOR 0.94, 95% CI 0.72, 1.23) and influenza vaccine was recorded in 61.8% of cases and 63.0% of controls (aOR 0.97, 95% CI 0.78, 1.19). Analyses that considered timing and combinations of vaccine receipt yielded similar estimates.
Conclusion: In this population, neither Tdap nor influenza vaccine receipt during pregnancy was associated with increased odds of clinical chorioamnionitis at delivery.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.